Results 131 to 140 of about 1,536,180 (350)
Current OncologyIntroduction: Advancements in oncology have revolutionized cancer treatment, with new drugs being approved at different rates worldwide. Our objective was to evaluate the approval of new oncological drugs for solid tumors by the Food and Drug ...
Rafael Balsini Barreto +2 more
doaj +1 more source
The Arduous Path to Drug Approval for the Management of Prader-Willi Syndrome: A Historical Perspective and Call to Action. [PDF]
Int J Mol Sci, 2023 Singh D +6 more
europepmc +1 more source
Molecular Oncology, EarlyView.Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef +10 more
wiley +1 more source
Drug approval prediction based on the discrepancy in gene perturbation effects between cells and humans. [PDF]
EBioMedicine, 2023 Park M, Kim D, Kim I, Im SH, Kim S.
europepmc +1 more source
Molecular Oncology, EarlyView.Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon +13 more
wiley +1 more source
From Concept to Regulatory Drug Approval: Lessons for Theranostics. [PDF]
J Nucl Med, 2022 Perera M, Morris MJ.
europepmc +1 more source
Molecular Oncology, EarlyView.Carcinoma‐associated fibroblasts (CAFs) in tumors influence cancer progression. We identified endoglin (ENG) as a key factor in TGF‐β signaling in myofibroblastic CAFs (myCAFs), linked to poor breast cancer outcomes. Inhibiting ENG on myCAFs suppressed the TGF‐β‐Smad2/3 pathway, reducing primary tumor growth and metastasis.
Shoki Okubo +11 more
wiley +1 more source
FDA New Drug Approval Times, Prescription Drug User Fees, and R & D Spending [PDF]
FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical R&D have likely increased.
Golec, Joseph H. +3 more
core +1 more source
Sometimes the Silence Can Be like the Thunder: Access to Pharmaceutical Data at the FDA [PDF]
, 2006 Those committed to the free exchange of scientific information have long complained about various restrictions on access to the FDA\u27s pharmaceutical data and the resultant restrictions on open discourse.
Ankelhed, Daniel +2 more
core +1 more source